Skip Navigation

Genetic Tool in Treatment-Resistant Depression

Title: Testing of a Genetic Tool in Treatment Resistant Depression (TRD)

Principal Investigator: Boadie Dunlop, MD

Population:  Patients with Major Depression over age 18 who are currently taking or have taken at least one antidepressant at some during this episode of depression and not responded to the medication. Patients must never have had ECT, TMS, or DBS treatment and have never met criteria for Bipolar disorder, Psychotic Disorder, Dementia, Autism Spectrum Disorder, or Schizophrenia. Patients with a current primary diagnosis of Panic Disorder, OCD, PTSD, or an eating disorder are also excluded.

Summary: This study aims to evaluate if a genetic test can help choose treatment for people with Major Depression. Participants will be randomly assigned to receive treatment informed by the additional component of their genetic profile or to be treated standard-of-care by the study psychiatrist without this information. The study will take place over approximately 26 weeks of which includes 2 weeks for screening, followed by the 12-week randomized treatment period. After the 12th week, all patients will receive their genetic information and be treated for another 12 weeks.

Procedure: General screening process, clinical ratings and diagnosis, physical exam, blood draw, saliva sample, urine collection, self-report questionnaires, treatment with an FDA-approved antidepressant.

Compensation: $20 for each study visit (excluding the screening visit). If eligible, the study compensates $100 total.

Phone (MAP Line): 404-778-6663 (MOOD)
Patients can go to: